Revive Therapeutic (RVV.C) announced they have entered into an agreement with the University of Health Sciences Antigua (UHSA) to collaborate with Revive on their novel psychedelic-assisted therapies and pioneering…
Search Results for: RVV.C – Page 4
Revive Therapeutics (RVV.C) entered into a memorandum of understanding with Indian pharmaceutical company, Supriya Lifescience, which includes manufacturing, clinical registration and commercialization for Bucillamine, according to a press release….
Revive Therapeutics (RVV.C), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare diseases, announced today that it has entered into…
Revive Therapeutics (RVV.C) signed a research agreement with the University of California, San Francisco (UCSF) to explore Bucillamine as a potential treatment for severe cases of COVID-19 today, according…
“Psilocybin offers a potential solution to manage moderate to severe cases of TBI,” stated RVV, “Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function…
Revive Therapeutics (RVV.C) announced they have completed research on and filed a patent application with the United States Patent and Trademark Office (USPTO) on an oral thin-film (OTF) delivery…
Revive Therapeutics (RVV.C) provided an update on their FDA Phase III clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate Covid-19. …
Revive Therapeutic (RVV.C) announced they have received positive results from a pre-clinical study evaluating the efficacy of psilocybin for the treatment of mild traumatic brain injury (TBI) in a rodent model of…
+135k shares in a downturn, my man The psychedelics sector is down bad this week. Just look at the psychedelics ETF PSYK.NE. It’s not an alarm or…
Revive Therapeutics (RVV.C) provided an update on their Phase 3 clinical trial for bucillamine for COVID-19 today. Primarily, the update’s about funding and more specifically their recent $23 million…